L1-79

DRUG2 trials

Sponsors

Yamo Pharmaceuticals LLC

Conditions

AutismAutism Spectrum Disorder

Phase 2

Safety of L1-79 in Adolescent and Adult Males With Autism

CompletedNCT02947048

Yamo Pharmaceuticals LLCAutism

Start: 2016-10-31End: 2018-02-01Updated: 2024-08-21

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

CompletedNCT05067582

Yamo Pharmaceuticals LLCAutism, Autism Spectrum Disorder

Start: 2022-01-25End: 2024-06-21Updated: 2024-07-31